Last updated: August 6, 2026
TISSUEBLUE is a 0.06% trypan blue ophthalmic surgical dye used to stain the internal limiting membrane and epiretinal membranes during vitreoretinal surgery. It is marketed by Dutch Ophthalmic Research Center International B.V. (DORC), which Carl Zeiss Meditec AG agreed to acquire in 2024. TISSUEBLUE is regulated as a medical device rather than as a conventional small-molecule pharmaceutical, so drug-style exclusivity, Orange Book listing, Paragraph IV litigation, and generic substitution do not directly apply.[1][2]
Public disclosures do not identify standalone TISSUEBLUE revenue, operating margin, unit volume, or product-level forecasts. Its financial trajectory must therefore be assessed through DORC’s surgical ophthalmology business and ZEISS Medical Technology’s portfolio strategy.
What is TISSUEBLUE and how is it used?
TISSUEBLUE is an intraocular staining product containing trypan blue at a concentration of 0.06%. Surgeons use it during pars plana vitrectomy to improve visualization of transparent or poorly visible tissues, particularly the internal limiting membrane and epiretinal membranes.[1]
What surgical procedures use TISSUEBLUE?
The product is used primarily in vitreoretinal procedures, including:
- Macular hole surgery
- Epiretinal membrane peeling
- Internal limiting membrane peeling
- Selected retinal detachment procedures
- Other vitreous and retinal surgeries requiring membrane visualization
TISSUEBLUE is not an injectable systemic medicine and does not compete with ophthalmic drugs used for glaucoma, retinal vascular disease, inflammation, or infection. Its commercial demand is linked to ophthalmic surgical procedure volumes, adoption of membrane-peeling techniques, hospital capital budgets, and the installed base of vitrectomy equipment.
What is the FDA status of TISSUEBLUE?
TISSUEBLUE received U.S. Food and Drug Administration approval through the premarket approval pathway. FDA records identify the product under PMA P190018, with approval in 2020.[1]
| Regulatory item |
Status |
| Product |
TISSUEBLUE |
| Active ingredient |
Trypan blue |
| Concentration |
0.06% |
| FDA pathway |
Premarket approval |
| FDA application |
PMA P190018 |
| Primary use |
Intraocular staining during vitreoretinal surgery |
| Regulatory category |
Medical device |
| U.S. approval timing |
2020 |
| Orange Book listing |
None identified |
| New chemical entity exclusivity |
Not applicable |
| Hatch-Waxman framework |
Not applicable |
The PMA pathway reflects the product’s use inside the eye and the FDA’s treatment of the product as a device. It does not create the same statutory exclusivity framework used for approved prescription drugs.
Does TISSUEBLUE have an Orange Book listing?
No conventional Orange Book listing applies. The FDA Orange Book covers approved drug products, while TISSUEBLUE is regulated as an ophthalmic surgical device. Competitors therefore do not enter through an abbreviated new drug application supported by Paragraph IV certification against listed patents.
What patents protect TISSUEBLUE?
Publicly available product and regulatory materials do not establish a clearly identifiable, product-specific U.S. patent estate that can be analyzed as a conventional pharmaceutical exclusivity position. The principal protection appears to arise from the combination of:
- FDA clearance through the PMA process
- Product quality and sterility controls
- Manufacturing know-how
- Packaging and intraocular-use specifications
- Distribution relationships
- Surgeon familiarity and hospital procurement status
- Integration with DORC’s vitreoretinal equipment and consumables portfolio
This protection is commercial and regulatory rather than equivalent to a composition-of-matter patent covering a new chemical entity.
Are formulation patents important for TISSUEBLUE?
Formulation and manufacturing controls can still affect competitive entry. An intraocular dye must meet requirements for sterility, concentration control, container compatibility, ocular safety, endotoxin limits, and shelf stability. These factors can create practical barriers even where no broad composition patent blocks a competing trypan blue product.
The existence, scope, enforceability, and expiration dates of any proprietary DORC patents or patent applications specifically covering TISSUEBLUE’s formulation, packaging, preparation, or use cannot be established from the product’s public FDA summary alone.
When does TISSUEBLUE lose exclusivity?
TISSUEBLUE does not have a single drug-patent expiration date that determines market entry. Its commercial exclusivity is governed by a combination of regulatory approval, manufacturing capability, surgeon adoption, procurement contracts, and DORC’s broader product ecosystem.
A competing manufacturer could pursue its own FDA pathway for a comparable intraocular staining device. That process would require independent evidence and compliance with applicable device requirements. A competitor would not necessarily need to challenge a TISSUEBLUE patent through Paragraph IV litigation.
Does TISSUEBLUE have FDA market exclusivity?
PMA approval gives the approved product a regulated market position, but it does not create a fixed five-year or seven-year drug exclusivity period. FDA device law does not map directly onto new chemical entity, orphan-drug, or pediatric exclusivity periods.
Which companies compete with TISSUEBLUE?
TISSUEBLUE competes in a specialized vitreoretinal staining segment. The principal competitive set includes:
| Company or product category |
Competitive relevance |
| DORC TISSUEBLUE |
0.06% trypan blue for intraocular tissue staining |
| Alcon |
Broad vitreoretinal surgery platform, instruments, accessories, and surgical dyes |
| Bausch + Lomb |
Ophthalmic surgical products and vitreoretinal market presence |
| Geuder |
European ophthalmic surgical consumables and staining products |
| Generic or private-label trypan blue products |
Potential price competition where regulatory requirements are met |
| Brilliant blue G products |
Alternative staining chemistry, particularly for internal limiting membrane procedures |
| Indocyanine green products |
Alternative dye used in selected retinal procedures, with different clinical and safety characteristics |
The competitive threat is broader than direct molecule-for-molecule substitution. Hospitals may evaluate a complete surgical system, including vitrectomy consoles, disposable packs, dyes, cannulas, forceps, illumination systems, and service support.
How does TISSUEBLUE compare with brilliant blue G?
Trypan blue and brilliant blue G are both used to improve visualization during retinal surgery, but clinical preference depends on the tissue targeted, surgeon technique, staining performance, safety profile, workflow, and local availability. TISSUEBLUE’s commercial position benefits from DORC’s established vitreoretinal surgery business, while alternative dyes may compete on staining characteristics or price.
What is the impact of the ZEISS-DORC transaction?
Carl Zeiss Meditec announced an agreement to acquire DORC in 2024 for approximately 985 million euros, subject to customary adjustments and closing conditions. The transaction expands ZEISS Medical Technology’s ophthalmic surgery portfolio into vitreoretinal surgery and adds DORC’s products, systems, and consumables to the ZEISS platform.[2][3]
The transaction has several implications for TISSUEBLUE:
- Distribution can expand through ZEISS’s global ophthalmic sales infrastructure.
- TISSUEBLUE can be bundled with DORC and ZEISS surgical equipment.
- Procurement leverage may increase where hospitals prefer integrated platforms.
- Product-level financial visibility may decrease because TISSUEBLUE will sit within a larger reporting structure.
- Cross-selling opportunities may support demand even if the dye itself remains a small revenue contributor.
The deal also increases the strategic value of consumables. A surgical dye can have modest standalone revenue but still support equipment utilization, recurring disposable sales, and customer retention.
What is the financial trajectory for TISSUEBLUE?
TISSUEBLUE’s standalone financial trajectory is not publicly reported. DORC is privately held, and Carl Zeiss Meditec reports at broader business-segment levels rather than disclosing revenue for individual surgical dyes.
What financial metrics are publicly available?
| Metric |
Public status |
| TISSUEBLUE revenue |
Not separately disclosed |
| TISSUEBLUE gross margin |
Not separately disclosed |
| TISSUEBLUE unit sales |
Not separately disclosed |
| TISSUEBLUE market share |
Not separately disclosed |
| DORC transaction value |
Approximately €985 million |
| Parent company reporting |
Segment-level, not product-level |
| Revenue model |
Recurring surgical consumable sales linked to procedures |
TISSUEBLUE likely has a consumables-oriented revenue model. Demand should track the number of vitreoretinal procedures, product penetration within DORC accounts, conversion from competing dyes, and the rate at which surgeons use membrane staining in routine practice.
What drives revenue growth?
The most important commercial drivers are:
- Growth in vitreoretinal surgery volumes
- Aging populations and higher prevalence of macular disease
- Increased diagnosis and treatment of epiretinal membranes and macular holes
- Expansion of retinal surgery capacity in emerging markets
- DORC’s installed base of vitrectomy systems
- Conversion of hospitals to DORC surgical packs
- ZEISS distribution and account access after acquisition
- Recurring use per procedure
Revenue growth is likely to be steady rather than comparable to a high-growth specialty pharmaceutical launch. The product addresses a narrow procedural use case, and its price per case is limited by hospital purchasing controls and the availability of alternative dyes.
What generic entry risks exist for TISSUEBLUE?
Generic-drug entry risk is low as a legal category because TISSUEBLUE is not an Orange Book-listed drug. Competitive entry risk remains present through substitute medical devices and independently approved ophthalmic dyes.
What could cause market share loss?
The main risks are:
- Lower-priced trypan blue products
- Alternative brilliant blue G formulations
- Hospital tendering and group purchasing pressure
- Private-label surgical consumables
- Reduced use of membrane staining in selected procedures
- Competitor bundling with vitrectomy systems
- Regulatory delays affecting product availability
- Manufacturing or supply interruptions
- Surgeon switching based on staining performance or workflow
The strongest defense is not necessarily a patent. It is integration into a broader surgical platform, validated quality performance, reliable supply, and established surgeon preference.
What patent litigation affects TISSUEBLUE?
No major publicly reported U.S. Paragraph IV litigation involving TISSUEBLUE has been identified. That outcome is consistent with the product’s device classification and absence from the Orange Book.
Potential disputes would more likely involve:
- Patent infringement claims concerning ophthalmic staining methods
- Trade-secret disputes over formulation or manufacturing
- Trademark disputes
- Regulatory or labeling disputes
- Contract disputes involving distribution or hospital procurement
- Product-liability claims relating to intraocular use
The absence of reported Paragraph IV litigation does not eliminate all intellectual-property risk. It means the primary legal risk does not follow the standard branded-drug versus generic framework.
What is the geographic coverage of TISSUEBLUE?
TISSUEBLUE’s commercial reach is tied to DORC’s international distribution network. DORC has historically operated in the ophthalmic surgical market across Europe, North America, Asia-Pacific, and other international regions. Product registration, labeling, reimbursement, and distributor access vary by jurisdiction.
The ZEISS transaction could improve geographic reach, particularly where ZEISS has established ophthalmic surgery sales and service infrastructure. Expansion remains dependent on local regulatory registrations and hospital procurement decisions.
How strong is the TISSUEBLUE commercial position?
TISSUEBLUE has a defensible niche position but not the economic profile of a high-value patented pharmaceutical. Its strengths include FDA approval, a specialized surgical indication, association with DORC’s vitreoretinal platform, and recurring procedural demand.
Its limitations include the absence of publicly demonstrated pharmaceutical-style exclusivity, limited product-level financial disclosure, a narrow addressable market, and the availability of alternative staining products.
Risk assessment
| Factor |
Assessment |
| Regulatory position |
Strong within approved device indication |
| Patent visibility |
Limited publicly established product-specific visibility |
| Generic-drug exposure |
Not applicable |
| Device substitution risk |
Moderate |
| Pricing power |
Moderate to limited |
| Recurring revenue quality |
Favorable |
| Dependence on procedure volumes |
High |
| Strategic value after ZEISS acquisition |
Potentially higher |
| Standalone valuation visibility |
Low |
| Manufacturing barrier |
Moderate due to ocular sterility and quality requirements |
What are the likely generic launch scenarios?
A direct “generic launch” is unlikely to follow the Hatch-Waxman model. Three competitive scenarios are more relevant:
Scenario 1: Stable niche leadership
DORC and ZEISS maintain distribution, surgeon adoption, and hospital contracts. TISSUEBLUE retains a stable position, with growth broadly tracking vitreoretinal procedure volumes.
Scenario 2: Price-led device competition
A competing manufacturer obtains the necessary regulatory authorization and undercuts price. Market share erosion is greatest in tenders and accounts that purchase dyes separately from surgical platforms.
Scenario 3: Platform-led expansion
ZEISS bundles TISSUEBLUE with vitreoretinal consoles, disposables, and service contracts. The product gains share through account-level selling even without major changes in the underlying retinal surgery market.
The third scenario is the most strategically important after the DORC acquisition.
Key Takeaways
- TISSUEBLUE is a 0.06% trypan blue intraocular surgical dye, not a conventional pharmaceutical.
- FDA approval was obtained through PMA P190018 in 2020.
- Orange Book listing, Paragraph IV certification, and Hatch-Waxman exclusivity do not apply.
- Public sources do not establish standalone TISSUEBLUE revenue, margin, volume, or market share.
- The product’s protection is primarily regulatory, manufacturing-based, commercial, and platform-oriented.
- DORC’s acquisition by Carl Zeiss Meditec for approximately 985 million euros increases distribution and bundling potential.
- Competitive risk comes from alternative dyes, private-label products, hospital tenders, and rival surgical platforms.
- The product should be evaluated as a recurring ophthalmic consumable within a broader vitreoretinal ecosystem rather than as a standalone high-value drug asset.
FAQs
Is TISSUEBLUE a drug or a medical device?
TISSUEBLUE is regulated as a medical device used for intraocular tissue staining during vitreoretinal surgery.
What company owns TISSUEBLUE?
TISSUEBLUE was developed and marketed by DORC. Carl Zeiss Meditec agreed to acquire DORC in 2024.
Does TISSUEBLUE have a generic equivalent?
There is no conventional FDA-approved generic pathway equivalent to an ANDA for TISSUEBLUE. Competing products may enter through separate medical-device or ophthalmic product authorization routes.
Can hospitals substitute another dye for TISSUEBLUE?
Substitution may be clinically and commercially possible, depending on the surgeon’s preference, the alternative product’s regulatory status, staining performance, safety profile, and hospital procurement rules.
Is TISSUEBLUE financially material to Carl Zeiss Meditec?
Standalone materiality cannot be determined from public reporting because Carl Zeiss Meditec does not separately disclose TISSUEBLUE revenue or profitability. Its strategic value is more likely tied to recurring consumables and support for the broader vitreoretinal platform.
References
- U.S. Food and Drug Administration. (2020). TISSUEBLUE, PMA P190018. FDA Premarket Approval Database. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm
- Carl Zeiss Meditec AG. (2024). ZEISS Medical Technology to acquire Dutch Ophthalmic Research Center. Company announcement. https://www.zeiss.com/meditec
- Carl Zeiss Meditec AG. (2024). Annual report and financial disclosures. https://www.zeiss.com/meditec/en/investor-relations.html
